These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15589469)

  • 1. Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors.
    Hohage H; Welling U; Heck M; Zeh M; Gerhardt U; Suwelack BM
    Int Immunopharmacol; 2005 Jan; 5(1):117-23. PubMed ID: 15589469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine and tacrolimus: influence on cardiovascular risk factors.
    Hohage H; Hillebrandt U; Welling U; Zeh M; Heck M; Gerhardt UW; Suwelack BM
    Transplant Proc; 2005 Mar; 37(2):1036-8. PubMed ID: 15848615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching immunosuppression from cyclosporine to tacrolimus improves long-term kidney function: a 6-year study.
    Hohage H; Welling U; Zeh M; Gerhardt U; Suwelack B
    Transplant Proc; 2005 May; 37(4):1898-9. PubMed ID: 15919497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients.
    Baid-Agrawal S; Delmonico FL; Tolkoff-Rubin NE; Farrell M; Williams WW; Shih V; Auchincloss H; Cosimi AB; Pascual M
    Transplantation; 2004 Apr; 77(8):1199-202. PubMed ID: 15114085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience of conversion from cyclosporine to tacrolimus prolonged-release in stabilized kidney transplant patients.
    Krejci K; Zadrazil J; Lackova E; Zilinska Z; Roland R; Dedinska I
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Sep; 160(3):407-11. PubMed ID: 27174195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of maintenance immunosuppression medication on the change in kidney allograft function.
    Gill JS; Tonelli M; Mix CH; Johnson N; Pereira BJ
    Kidney Int; 2004 Feb; 65(2):692-9. PubMed ID: 14717943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus.
    Zawiasa A; Szklarek-Kubicka M; Fijałkowska-Morawska J; Nowak D; Rysz J; Mamełka B; Nowicki M
    Transplant Proc; 2009; 41(1):188-91. PubMed ID: 19249511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
    Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
    Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation.
    Batista F; Auyanet I; Torregrosa JV; Oppenheimer F
    Transplant Proc; 2012 Nov; 44(9):2582-4. PubMed ID: 23146461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy.
    Stoves J; Newstead CG; Baczkowski AJ; Owens G; Paraoan M; Hammad AQ
    Nephrol Dial Transplant; 2004 Aug; 19(8):2113-20. PubMed ID: 15161956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study.
    Marcén R; Chahin J; Alarcón A; Bravo J
    Transplant Proc; 2006 Oct; 38(8):2427-30. PubMed ID: 17097957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation.
    Kolonko A; Chudek J; Wiecek A
    Transplant Proc; 2011 Oct; 43(8):2950-3. PubMed ID: 21996198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation.
    Helmschrott M; Rivinius R; Ruhparwar A; Schmack B; Erbel C; Gleissner CA; Akhavanpoor M; Frankenstein L; Ehlermann P; Bruckner T; Katus HA; Doesch AO
    Drug Des Devel Ther; 2015; 9():1217-24. PubMed ID: 25759566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus.
    Chamienia A; Biedunkiewicz B; Król E; Debska-Slizień A; Rutkowski B
    Transplant Proc; 2006; 38(1):81-5. PubMed ID: 16504670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy.
    Videla CO
    Transplant Proc; 2009; 41(6):2659-63. PubMed ID: 19715995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of renal function improvement following tacrolimus conversion in cyclosporine-treated kidney transplant recipients.
    Chang HR; Lin CC; Lian JD
    Transplant Proc; 2007 Dec; 39(10):3135-41. PubMed ID: 18089339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine.
    Sanchez V; Delgado JF; Morales JM; Tello R; Gómez MA; Escribano P; de la Cámara AG; de la Calzada CS
    Transplant Proc; 2004 Nov; 36(9):2823-5. PubMed ID: 15621159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
    Falck P; Vethe NT; Asberg A; Midtvedt K; Bergan S; Reubsaet JL; Holdaas H
    Nephrol Dial Transplant; 2008 Mar; 23(3):1048-53. PubMed ID: 17956893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.